

2/16/97

* U. S. P A T E N T T E X T F I L E *

* *

=> s hcmv-mie

189 HCMV

420 MIE

L1 4 HCMV-MIE

(HCMV(W)MIE)

=> d 11 1-4 cit,ab

1. 5,591,639, Jan. 7, 1997, Recombinant DNA expression vectors;
Christopher R. Bebbington, 435/320.1, 172.3; 536/24.1, 24.2 [IMAGE
AVAILABLE]

US PAT NO: 5,591,639 [IMAGE AVAILABLE]

L1: 1 of 4

ABSTRACT:

The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the **hCMV**-**MIE** DNA linked directly to the coding sequence of a heterologous gene are described. Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the **hCMV**-**MIE** DNA for expression of a heterologous gene are also included within the invention.

2. 5,585,237, Dec. 17, 1996, Methods and compositions for high protein production from recombinant DNA; Hermann Oppermann, et al., 435/6, 172.3, 240.2 [IMAGE AVAILABLE]

US PAT NO: 5,585,237 [IMAGE AVAILABLE]

L1: 2 of 4

ABSTRACT:

Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, constitutively expressing immortalized mammalian cell lines that exhibit high recombinant protein productivity while maintaining a low copy number per cell of the non-native recombinant DNA sequence encoding the protein of interest.

3. 5,443,953, Aug. 22, 1995, Preparation and use of immunoconjugates; Hans J. Hansen, et al., 424/1.49, 1.53, 9.341, 178.1, 179.1, 180.1, 181.1, 182.1, 183.1; 435/7.1, 7.2, 7.23, 69.6, 172.1; 530/387.3, 391.3, 391.5, 391.7, 391.9 [IMAGE AVAILABLE]

US PAT NO: 5,443,953 [IMAGE AVAILABLE]

L1: 3 of 4

ABSTRACT:

The present invention relates to immunoconjugates comprising an antibody fragment which is covalently bound to a diagnostic or therapeutic principle through a carbohydrate moiety in the light chain variable region of the antibody fragment. The invention also relates to immunoconjugates comprising an antibody moiety that is an intact antibody containing a glycosylation site in the light chain variable domain which has been introduced into the antibody by mutating the nucleotide sequence

encoding the light chain. The resultant immunoconjugates retain the immunoreactivity of the antibody fragment or intact antibody, and target the diagnostic or therapeutic principle to a target tissue where the diagnostic or therapeutic effect is realized. Thus, the invention contemplates the use of such immunoconjugates for diagnosis and immunotherapy. The invention further relates to methods for preparing such immunoconjugates.

4. 5,004,810, Apr. 2, 1991, Antiviral oligomers; Kenneth G. Draper, 536/24.5, 23.72, 24.1 [IMAGE AVAILABLE]

US PAT NO: 5,004,810 [IMAGE AVAILABLE]

L1: 4 of 4

ABSTRACT:

Oligomers that are complementary in base sequence to the initiation region on mRNA coding for herpes simplex virus transactivating proteins inhibit the replication of the virus.

=> e bebbington, christopher r./in

E#	FILE	FREQUENCY	TERM
--	---	-----	-----
E1	USPAT	10	BEBBER, HANS J/IN
E2	USPAT	1	BEBBINGTON, ANTHONY J/IN
E3	USPAT	2	--> BEBBINGTON, CHRISTOPHER R/IN
E4	USPAT	1	BEBBINGTON, JOHN JR/IN
E5	USPAT	1	BEBBINGTON, JOHN R W/IN
E6	USPAT	1	BEBBINGTON, JULIE C/IN
E7	USPAT	1	BEBBINGTON, SAMUEL T/IN
E8	USPAT	1	BEBBS, JOSEPH F JR/IN
E9	USPAT	1	BEBE, HANS J/IN
E10	USPAT	1	BEBEAU, JERALD R/IN
E11	USPAT	1	BEBECH, MICHAEL J/IN
E12	USPAT	2	BEBEE, JACK G/IN

=> s e3

L2 2 "BEBBINGTON, CHRISTOPHER R"/IN

=> d 12 1-2 cit,ab

1. 5,591,639, Jan. 7, 1997, Recombinant DNA expression vectors; **Christopher R. Bebbington**, 435/320.1, 172.3; 536/24.1, 24.2 [IMAGE AVAILABLE]

US PAT NO: 5,591,639 [IMAGE AVAILABLE]

L2: 1 of 2

ABSTRACT:

The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described. Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.

2. 5,122,464, Jun. 16, 1992, Method for dominant selection in eucaryotic cells; Richard H. Wilson, et al., 435/172.3, 320.1 [IMAGE AVAILABLE]

US PAT NO: 5,122,464 [IMAGE AVAILABLE]

L2: 2 of 2

ABSTRACT:

Recombinant DNA sequences which encode the complete amino acid sequence of a glutamine synthetase, vectors containing such sequences, and methods for their use, in particular as dominant selectable markers, for use in co-amplification of non-selected genes and in transforming host cell lines to glutamine independence.

=>